Previous close | 1.0600 |
Open | 0.8500 |
Bid | 0.8098 x 400 |
Ask | 0.8404 x 700 |
Day's range | 0.8000 - 0.9000 |
52-week range | 0.5010 - 3.5900 |
Volume | |
Avg. volume | 1,460,672 |
Market cap | 41.831M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Despite a net loss, Eyenovia progresses with FDA approvals and strategic commercial expansions.
Eyenovia (EYEN) plunges 18% after sharing plans to consider strategic alternatives involving the sale of the company or assets, amid a severe cash crunch and poor performance of marketed drugs.
Q4 2023 NovaBay Pharmaceuticals Inc Earnings Call